

| | | | | | | | |
|--|-----|---|--|--|--|------------------------------|--|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 4292-0048-55 | | SERIAL NO. 09/027,671 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Alan K. SMITH, et al. | | | |
| | | | | FILING DATE February 23, 1998 | | GROUP | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | AAA | Riddell SR, Greenberg PD. 1990. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189-201. | | | | | |
| | AAB | Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. 2002a. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854. | | | | | |
| | AAC | Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10): 2346-57. | | | | | |
| | AAD | Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J, Leitman S, Steinberg SM, Rosenberg SA, Yang YC. 1994. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother 38:299-303. | | | | | |
| | AAE | Ridolfi L, Ridolfi R, Riccobon A, De Paola F, Petrini M, Stefanelli M, Flamini E, Ravaioli A, Verdecchia GM, Trevisan G, Amadori D. 2003. Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma. J Immunother 26:156-162. | | | | | |
| | AAF | Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, Rosenberg SA, Topalian SL. 1994. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 12:1475-1483. | | | | | |
| | AAG | Rufer N, W.Dragowska, G.Thornbury, E.Roosnek, and P.M.Lansdorp. 1998. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat.Biotechnol. 16:743-747. | | | | | |
| | AAH | Reed,J.R., M.Vukmanovic-Stejic, J.M.Fletcher, M.V.Soures, J.E.Cook, C.H.Orteu, S.E.Jackson, K.E.Birch, G.R.Foster, M.Salmon, P.C.Beverley, M.H.Rustin, and A.N.Akbar. 2004. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J.Exp.Med. 199:1433-1443 | | | | | |
| | AAI | Blackburn,E.H. 2001. Switching and signaling at the telomere. Cell 106:661-673. | | | | | |
| | AAJ | de Lange,T. 2002. Protection of mammalian telomeres. Oncogene 21:532-540 | | | | | |
| | AAK | Zhou,J., X.Shen, R.J.Hodes, S.A.Rosenberg, and P.Robbins. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J.Immunol. 175:7046-7052. | | | | | |
| | AAL | | | | | | |
| | AAM | | | | | | |
| | AAN | | | | | | |
| | AAO | | | | | | |
| | AAP | | | | | | |
| | AAQ | | | | | | |
| Examiner | | | | Date Considered | | | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |